Pharmaceutical industry interactions of psychiatric trainees from 20 European countries

Abstract

There are frequent interactions between European psychiatric trainees and the PI, with significant variation between countries. We identified several factors affecting this interaction, including attribution of an educational role to the PI. Creating alternative educational opportunities and specific training dedicated to PI interactions may therefore help to reduce the impact of the PI on psychiatric training.

National survey of pain clinics in Croatia: Organization and services

“…It has been shown that contact with pharmaceutical companies should be limited in order to obtain prescribing treatment based on scientific evidence (37). In the Croatian Health Care system, pharmaceutical companies frequently send their representatives to meet with physicians (38). There is a Contract from 2010 on ethical marketing aimed towards regulating contacts between representatives of pharmaceutical companies and physicians, but it is not known what the effects of this Contract are (39).…”

Prescription preferences in antipsychotics and attitude towards the pharmaceutical industry in Belgium

“…The role and impact of the pharmaceutical industry on prescription patterns has been increasingly debated and several surveys have given researchers interesting insights into this subject 1. A recent systematic review2 reports about 29 studies looking at the impact of visits of drug representatives (reps).…”

Dangerous liaisons: doctors‐in‐training and the pharmaceutical industry

“…In the United States, a national survey demonstrated that more than half of early physician trainees had received a gift of some form from a representative, while over a third had attended industry‐sponsored education sessions . In Europe, a cross‐sectional analysis of psychiatry trainees in 20 countries showed the mean number of encounters with representatives ranged from once to 20 times a month . This is important as doctors‐in‐training are at a particularly vulnerable stage of their careers with regard to developing relationships with the pharmaceutical industry.…”

“…4 In Europe, a cross-sectional analysis of psychiatry trainees in 20 countries showed the mean number of encounters with representatives ranged from once to 20 times a month. 5 This is important as doctors-in-training are at a particularly vulnerable stage of their careers with regard to developing relationships with the pharmaceutical industry. Residents have been shown in the United States to have little knowledge regarding these relationships, 6 and poor insight into the ramifications of their interactions with pharmaceutical representatives on patient care.…”